Waheed Jamal
- Health
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction
Ingelheim, Germany: – The positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in…
Read More » - Business
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Copenhagen, Denmark & Ingelheim, Germany: New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH.…
Read More » - United States
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Ingelheim, Germany & Indianapolis, United States: – In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total…
Read More » - World
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Ingelheim, Germany: No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard…
Read More »